Mural im La Mission District San Francisco (Aufnahme Oncoletter)
Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Link to Posters: Sie müssen bei ASCO-GU eingeloggt sein und über eine aktuelle Registrierung verfügen, um auf die Poster dieser Sitzung zugreifen zu können. Hier können Sie die Registrierung erwerben.
A phase 2 study of the combination dostarlimab with niraparib in patients with penile carcinoma that has progressed following chemotherapy.
Robin Neubauer, CCRP, BSN, RN.H. Lee Moffitt Cancer Center and Research Institute
A phase II trial of cemiplimab alone or in combination with standard of care chemotherapy in locally advanced or metastatic penile carcinoma (EPIC trial).
Amit Bahl, MD, FRCP, FRCR. Bristol Haematology and Oncology Centre, University Hospitals Bristol and Weston NHS Foundation Trust
International multicenter real-world registry for patients with metastatic renal cell carcinoma: Meet-URO 33 study (REGAL study).
Giuseppe Fornarini, MD. Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino
A phase I/II, open label, single arm study on safety, tolerability and anti-tumour effiacy of orellanine treatment in patients with metastatic clear-cell or papillary renal cell carcinoma.
Sven Lundstam, MD, PhD. Departments of Oncology and Urology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg
Strategic treatment pause of first-line immune checkpoint inhibitor + VEGFR-tyrosine kinase inhibitor in patients with good or intermediate risk metastatic renal cell carcinoma (mRCC) in response at 1 year of treatment (SPICI-GETUG R05): A non-inferiority randomized clinical trial.
Marine Gross-Goupil, MD, PhD. Centre Hospitalo-Universitaire Saint André
Neoadjuvant pembrolizumab (PEMBRO) and axitinib (AXI) in renal cell carcinoma with associated inferior vena cava tumor thrombus (NEOPAX).
Stephanie Lakritz. University of Colorado
Phase III randomized trial of stereotactic ablative radiotherapy (SAbR) for oligometastatic advanced renal carcinoma (EA8211-SOAR).
Raquibul Hannan, MD, PhD. University of Texas Southwestern Medical Center
The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in immune-oncology era (SEVURO-CN): A study protocol for a multi-center, prospective, randomized trial.
Jee Soo Park, MD, PhD. Department of Urology and Urological Science Institute, Yonsei University College of Medicine
Combination nivolumab and ipilimumab with and without camu camu in first-line treatment of metastatic renal cell carcinoma (mRCC).
Regina Barragan-Carrillo, MD. City of Hope Comprehensive Cancer Center
Advanced renal cell cancer combination immunotherapy clinical trial (ARCITECT; HCRN GU 22-587).
Michael Thomas Serzan, MD. Dana-Farber Cancer Institute
SWOG S2200 (PAPMET2): A phase II randomized trial of cabozantinib with or without atezolizumab in patients with advanced papillary renal cell carcinoma (PRCC).
Benjamin L. Maughan, MD, PharmD. Huntsman Cancer Institute at the University of Utah
Phase II study of axitinib intensification compared to nivolumab alone after induction with ipilimumab plus nivolumab in patients with mRCC without previous complete response (AxIn study).
Chiara Ciccarese, MD, PhD. Oncology Unit, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Catholic University of Rome
Efficacy of perioperative pembrolizumab treatment in patients with resectable metastases from kidney cancer: The PE-PE study.
Roberto Iacovelli, MD, PhD. Fondazione Policlinico Universitario A. Gemelli, IRCCS
Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC.
Eric Jonasch, MD. The University of Texas MD Anderson Cancer Center
A multi-center, open-label phase II study of lenvatinib plus pembrolizumab (LEAP) in patients with renal cell carcinoma with brain metastasis previously treated with immune checkpoint blockade.
Elshad Hasanov, MD, PhD. The Ohio State University Comprehensive Cancer Center - The James
Multiomics approach for patient stratification and novel target identification in metastatic clear cell renal carcinoma (Meet-URO 31).
Melanie Claps, MD. Genitourinary Medical Oncology, Medical Oncology Department, Fondaione IRCCS Istituto Nazionale Tumori
P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-45 years with intermediate and poor-risk metastatic germ cell tumours (GCTs).
Martin R. Stockler, MBBS, FRACP, MS. NHMRC Clinical Trials Centre, The University of Sydney
Improving health education through a patient-clinician partnered intervention in the patient with genitourinary cancer.
Jessica Parker. University of Michigan
PRECISION 1: A phase 2, multicenter, open-label basket trial of nab-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2.
Gopa Iyer, MD. Memorial Sloan Kettering Cancer Center